In 2016, there were over 1.6 million new cancer patients and five hundred thousand cancer-related deaths in the US. It’s such statistics that has prompted researchers to work towards developing a cure. Well, there is a recent breakthrough where scientists believe they are close to the vaccine.
The pronouncement was made via publication by Prof. Dr. Ronald Levy, lead researcher and Professor of Oncology at Stanford University School of Medicine. The “medical- changing” development was arrived at following the successful removal of lymphoma tumor from laboratory mice. For a while now, scientists have been conducting tests on mice by introducing on various parts of the body.
“Our approach uses a one-time application of very small amounts of two agents to stimulate the immune cells within the tumor itself,” stated the Professor.
The scientists began by picking a bunch of mice and isolated them. They were then injected with solid lymphoma tumor in two parts of the body. After this, a small amount of agent was induced to the affected parts.
The T-cells contained in the two agents had worn off the jab tumor in the 87 out of the 90 mice. Interestingly, the antibodies had moved to other infected parts of the body and extended the rodents’ lifespan.
“I don’t think there’s a limit to the type of tumor we could potentially treat, as long as it has infiltrated by the immune system,” stated the Lead author. it’s with such sentiments that there is some hope in delivering cancer cure.
On the downside, the agents can only be used for the same type of cancer. For example, if the solution was introduced on lung cancer it didn’t work on breast cancer.
New Approach to Human Cancer
Scientists have over the years integrated radiations and chemotherapy in cancer treatment. This has however proven to pose adverse side effects on the patients. It is the need to do away with the effects that led researchers to improvise on the T-cells.
“This approach bypasses the need to identify tumor-specific immune targets and doesn’t require wholesale activation of the immune system or customization of a patient’s immune cells,” said Dr. Levy. He shared the remarks being a pioneer in the study of immune system having even developed one of the initial monoclonal antibodies for .
However, the success of this alternative had been stalled by the weakening of the injected antibodies after some time which enables the tumor cells to overpower the immune system. Notably, the replication of the said vaccine will have to wait for the certification of one of the agents to be used in the vaccine.
An Affordable Solution
When it comes to cancer treatment the burden of the heavy costs is often felt by the patients and their families. The good news is that the new treatment will reprieve patients of the agony of side effects experienced after undergoing therapy.
“This approach bypasses the need to identify tumor-specific immune targets and doesn’t require wholesale activation of the immune system or customization of a patient’s immune cells,” assured Dr. Ronald Levy.
An example of an expensive procedure is the T-cell treatment. This is because it entails the removal of the patients T-cell to reconfigure the cell structure then re-introduce back to the body. Apart from it being exorbitant, the current treatments don’t have a 100 percent cure rate.
Researchers are looking for fifteen patient volunteers with different to test the drug on. This gives them a chance to make an observation on the efficiency of the drug. If all goes well then the jab tumors should disappear.
It’s at this stage that the world keenly follows the progress made in this exciting cancer treatment method.